Loading...
XWAR
NEU
Market cap1.02bUSD
Dec 05, Last price  
818.00PLN
1D
-0.61%
1Q
20.29%
Jan 2017
109.74%
IPO
1,793.52%
Name

Neuca SA

Chart & Performance

D1W1MN
XWAR:NEU chart
P/E
23.79
P/S
0.29
EPS
34.39
Div Yield, %
1.76%
Shrs. gr., 5y
-0.19%
Rev. gr., 5y
8.78%
Revenues
12.61b
+6.76%
1,414,766,0001,700,854,0003,288,786,0003,969,629,0005,687,344,0006,131,679,0006,388,658,0005,687,431,0005,795,092,0006,568,700,0006,945,703,0007,077,194,0007,485,234,0007,753,263,0008,278,727,0009,254,014,0009,864,258,00011,232,540,00011,812,636,00012,611,751,000
Net income
154m
+5.45%
10,810,00011,275,00016,350,00014,104,00036,336,00037,563,00053,192,00066,016,00085,347,00093,070,000101,284,000111,727,00094,497,00098,274,000117,655,000141,791,000150,655,000137,238,000146,269,000154,244,000
CFO
63m
-78.07%
13,200,000-11,013,00084,072,00035,614,00048,994,00014,111,000166,079,000124,920,00027,696,000202,556,000180,402,000175,049,000121,764,000121,935,000202,247,000324,671,000300,198,000335,937,000288,271,00063,229,000
Dividend
Jun 12, 202414.5 PLN/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

NEUCA S.A. engages in the distribution of pharmaceuticals to pharmacies and hospitals in Poland. It operates through Pharmaceutical Wholesale; Own Brands; and Outpatient Care Clinics, Clinical Trials and Telemedicine segments. The company also provides advertising and marketing services; pharmaceutical products under its own brand; clinical trial, telemedicine, agency, financial, road cargo transport, accounting and bookkeeping, software, hospital, and information technology and computer related services; and health, property, and other personal insurance products. In addition, it operates outpatient care clinics and medical stores. The company was formerly known as Torfarm SA and changed its name to NEUCA S.A. in April 2010. NEUCA S.A. was founded in 1990 and is based in Torun, Poland.
URL
https://www.neuca.pl/
IPO date
Sep 30, 2004
Employees
3,981
Domiciled in
PL
Incorporated in
PL

Valuation

Title
PLN in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT